FP759A PHARMACOECONOMIC ANALYSIS OF PHOSPHATE BINDERS COST-EFFECTIVENESS IN THE RISCAVID STUDY [PDF]
, 2015 M. Migliori +9 more
openalex +1 more source
Aging and Cancer, EarlyView.Natural products target the aging kidney in diabetic nephropathy by restoring the AMPK–SIRT1–Nrf2 axis, reducing oxidative stress, inflammation, fibrosis, and cellular senescence while enhancing mitochondrial biogenesis and antioxidant defenses.
Sherif Hamidu +8 more
wiley +1 more source
Bicarbonate therapy, phosphate binders, and risk for vascular calcification [PDF]
, 2014 Beatriz Fernández‐Fernández +2 more
openalex +1 more source
Aging Is a Key Driver for Adult Acute Myeloid Leukemia
Aging and Cancer, EarlyView.Acute myeloid leukemia (AML) is a classical age‐related hematologic malignancy, and a key driver of AML is aging, which profoundly regulates intrinsic factors such as genomic instability, epigenetic reprogramming, and metabolic dysregulation, and alters bone marrow microenvironment.
Rong Yin, Haojian Zhang
wiley +1 more source
Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model. [PDF]
Drugs R D, 2017 Brunelli SM +5 more
europepmc +1 more source
Developmental and Epileptic Encephalopathy due to Biallelic Pathogenic Variants in PIGM
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective PIGM encodes a critical enzyme in the glycosylphosphatidylinositol (GPI)‐anchor biosynthesis pathway. While promoter‐region mutations in PIGM have been associated with a relatively mild phenotype characterized by portal vein thrombosis and absence seizures, recent evidence suggests that coding‐region mutations result in a more severe
Júlia Sala‐Coromina +11 more
wiley +1 more source
Thermal insulating cementitious composite containing aerogel and phosphate-based binder
, 2019 Mojtaba Baghban
openalex +1 more source
FP619LONG-TERM SAFETY AND EFFICACY OF IRON-BASED PHOSPHATE BINDERS, FERRIC CITRATE HYDRATE VERSUS SUCROFERRIC OXYHYDROXIDE, ON HYPERPHOSPHATEMIA IN CHRONIC HEMODIALYSIS PATIENTS [PDF]
, 2018 Hiroyuki Matsushima +4 more
openalex +1 more source
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants
Annals of Clinical and Translational Neurology, EarlyView.Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold +12 more
wiley +1 more source